Methods of administering anti-cd38 antibody
AssigneeSanofi
InventorsHeloise AUDAT, Sylvia MARION, Frank CAMPANA ZAMBRANO
Life of this patent
Estimating the term…
Loading patent…
AssigneeSanofi
InventorsHeloise AUDAT, Sylvia MARION, Frank CAMPANA ZAMBRANO
Estimating the term…
Provided are methods of treating a human individual having multiple myeloma that comprise administering to the individual 10 mg/kg isatuximab via intravenous infusion, wherein the volume of each infusion of 10 mg/kg isatuximab is 250 ml. Also provided are methods of treating a human individual having multiple myeloma that comprise administering an anti-CD38 antibody in 28-day cycles, wherein the anti-CD38 antibody is administered on Days 1, 8, 15, and 22 of a first 28-day cycle, wherein the CD38-antibody is administered on Days 1 and 15 of every 28-day cycle following the first 28-day cycle; and wherein the anti-CD38 antibody is administered at a dose of 10 mg/kg or 20 mg/kg.
(canceled)
A method of administering an anti-CD38 antibody to a human individual in need thereof, wherein the individual has multiple myeloma, comprising administering to the individual at least a first dose of the anti-CD38 antibody by intravenous infusion, wherein the anti-CD38 antibody is administered at a dose of at least 10 mg/kg, wherein the dose of the anti-CD38 antibody is in a volume of 250 ml, and wherein the anti-CD38 antibody is isatuximab.
3-4. (canceled)
(canceled)
8-10. (canceled)
12-13. (canceled)
15-16. (canceled)
19-20. (canceled)
(canceled)
A method of administering an anti-CD38 antibody to a human individual in need thereof, wherein the individual has multiple myeloma, comprising administering to the individual at least three doses of the anti-CD38 antibody by intravenous infusion, wherein the anti-CD38 antibody is administered at a dose of at least 10 mg/kg, wherein the dose of the anti-CD38 antibody is in a volume of 250 ml, and wherein the anti-CD38 antibody is isatuximab;
24-25. (canceled)
27-47. (canceled)
A method of safely administering an anti-CD38 antibody to a human individual in need thereof, wherein the individual has multiple myeloma, comprising administering to the individual at least a first dose of the anti-CD38 antibody via intravenous infusion, wherein the anti-CD38 antibody is administered at a dose of at least 10 mg/kg in a volume of 250 ml, wherein the first dose is infused over a duration of about 1.5 and about 6.5 hours, and wherein the anti-CD38 antibody is isatuximab.
49-50. (canceled)
54-59. (canceled)
A method of treating a human individual having multiple myeloma, comprising administering to the individual an anti-CD38 antibody, pomalidomide, and dexamethasone,
61-70. (canceled)
73-84. (canceled)
An intravenous bag containing between about 360 mg and 1600 mg of an anti-CD38 antibody in a volume of 250 ml, wherein the wherein the anti-CD38 antibody is isatuximab.
Dependencies are inferred from the claim text.